2025年1月4日 · The role of VEGF in diabetic retinopathy. Diabetic retinopathy is a common complication of diabetes that affects the eyes and can lead to vision loss if left untreated. In this condition, high blood sugar levels cause damage to the blood vessels in the retina, leading to leakage, swelling, and ultimately, vision impairment.

2014年3月8日 · Based on the crucial pathogenic role of vascular endothelial growth factor (VEGF) in the development of diabetic macular edema (DME), intravitreal anti-VEGF agents have emerged as new treatments. To provide an understanding of the rationale for use and clinical efficacy of anti-VEGF treatment, we examine this topic in a two-part Bench to Clinic ...

Keywords: Diabetic retinopathy, VEGF, DME, diabetes, central retinal vein occlusion, PGF. INTRODUCTION. Diabetic retinopathy (DR), a well-known consequence of long-standing and poorly controlled diabetes mellitus (DM), causes significant vision loss and blindness in …

Diabetic retinopathy remains the leading vascular-associated cause of blindness throughout the world. Its treatment requires a multidisciplinary interventional approach at both systemic and local levels. Current management includes laser photocoagulation, …

2014年3月8日 · Now, it is widely anticipated that the use of ocular anti-VEGF therapy will be extended to treat the vision-threatening forms of diabetic retinopathy (), which affect an estimated 28 million people around the world ().In this two-part Bench to Clinic narrative, the Bench article by Simó et al. reviews the pathophysiological role of …

Keywords: diabetic retinopathy, vascular endothelial growth factor, VEGF, anti-VEGF, intravitreal injection, eye. 1. Introduction. Diabetic retinopathy (DR) is a significant public health concern as the leading cause of vision loss in people with diabetes. DR can cause permanent, disabling vision loss that affects either peripheral or central ...

2025年3月1日 · For proliferative diabetic retinopathy, DeWilde reviewed clinical trial data comparing anti-VEGF therapy with panretinal photocoagulation (PRP), noting similar visual acuity outcomes at 2 and 5 ...

Vascular endothelial growth factor (VEGF) is one of the most important mediators involved in the pathogenesis of diabetic retinopathy (DR). The abnormal production and release of VEGF induces vascular endothelial cell proliferation and migration and increased vascular permeability [ 1 ].

Based on the crucial pathogenic role of vascular endothelial growth factor (VEGF) in the development of diabetic macular edema (DME), intravitreal anti-VEGF agents have emerged as new treatments. To provide an understanding of the rationale for use and clinical efficacy of anti-VEGF treatment, we examine this topic in a two-part Bench to Clinic ...

Anti–vascular endothelial growth factor (VEGF) agents given as intravitreous injections are well-established and effective treatments for the 2 major vision-threatening complications of diabetic retinopathy (DR): center-involved diabetic macular edema (CI-DME) and proliferative DR (PDR). 1,2 Together, these 2 complications account for the ...